View pictures in App save up to 80% data.
Liu Jingzhen waving at the journalists after conference. [photo /Associated Press]
After the world's historical pandemic, COVID-19 was first reported in Wuhan in late 2019, it soon spread to other parts of the world and currently, more than 1.1 million people have died from the disease. More than 40 million cases have too been recorded as per the data in John Hopkins University website.
With the closing down of schools, businesses and restricting movements to minimize interpersonal spread of the disease, it is no longer secret that economies of many world's countries have gone down owing to COVID-19.
However, it may sound like good news to the world especially to the developing countries from Chinese state owned drugs manufucturer.
Speaking to the news conference as reported by Associated Press, SinoPharm group's chairman informed that their trial drugs were in theie final stages before being approved for use.
According to Liu Jingzhen, the group's chairman, two candidate drugs potential of being approved have now been tested in 50,000 people in 10 countries. About results, the chairman reported that trial tests results were promising.
Mr Jingzhen said at the moment, the company is setting up two production lines both in Wuhan and Beijing which will produce upto 1 billion drugs by next year January.
"The production capacity will reach 1 billion doses next year, ensuring sufficient safety," said Liu. View pictures in App save up to 80% data.
SinoPharm is one of the companies racing to find possible coronavirus vaccines. Other companies outside China are Astrazeneca and Mordena.